AMGN
NASDAQAmgen Inc.
Price$440.36+0.02 (+0.00%)
01:30 PM02:00 PM
News · 26 weeks128+350%
2026-03-012026-08-23
Mix2790d
- Analyst9(33%)
- Insider7(26%)
- Other4(15%)
- Dividends4(15%)
- SEC Filings2(7%)
- Earnings1(4%)
Latest news
25 items- INSIDERSVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability4 - AMGEN INC (0000318154) (Issuer)
- INSIDERVP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERSVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERSVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)4 - AMGEN INC (0000318154) (Issuer)
- ANALYSTTruist reiterated coverage on Amgen with a new price targetTruist reiterated coverage of Amgen with a rating of Hold and set a new price target of $362.00 from $340.00 previously
- ANALYSTOppenheimer reiterated coverage on Amgen with a new price targetOppenheimer reiterated coverage of Amgen with a rating of Outperform and set a new price target of $450.00 from $400.00 previously
- ANALYSTMorgan Stanley reiterated coverage on Amgen with a new price targetMorgan Stanley reiterated coverage of Amgen with a rating of Equal-Weight and set a new price target of $351.00 from $333.00 previously
- ANALYSTRBC Capital Mkts reiterated coverage on Amgen with a new price targetRBC Capital Mkts reiterated coverage of Amgen with a rating of Outperform and set a new price target of $400.00 from $370.00 previously
- ANALYSTRobert W. Baird reiterated coverage on Amgen with a new price targetRobert W. Baird reiterated coverage of Amgen with a rating of Underperform and set a new price target of $230.00 from $215.00 previously
- ANALYSTBofA Securities reiterated coverage on Amgen with a new price targetBofA Securities reiterated coverage of Amgen with a rating of Underperform and set a new price target of $317.00 from $312.00 previously
- ANALYSTCanaccord Genuity reiterated coverage on Amgen with a new price targetCanaccord Genuity reiterated coverage of Amgen with a rating of Hold and set a new price target of $384.00 from $366.00 previously
- ANALYSTWells Fargo reiterated coverage on Amgen with a new price targetWells Fargo reiterated coverage of Amgen with a rating of Equal Weight and set a new price target of $400.00 from $390.00 previously
- ANALYSTBMO Capital Markets reiterated coverage on Amgen with a new price targetBMO Capital Markets reiterated coverage of Amgen with a rating of Outperform and set a new price target of $450.00 from $400.00 previously
- SECAmgen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AMGEN INC (0000318154) (Filer)
- PRAMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSTHOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2026."Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade," said Robert A. Bradway, chairman and chief executive officer.Key results include:For the second quarter, total revenues increased 10% to $10.1 billion in comparison to
- SECSEC Form 8-K filed by Amgen Inc.8-K - AMGEN INC (0000318154) (Filer)
- PRAMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDENDTHOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026. The dividend will be paid on September 11, 2026, to all stockholders of record as of the close of business on August 21, 2026.About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the c
- PRAMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTSTHOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentation
- FDAFDA Approval for REPATHA issued to AMGEN INCSubmission status for AMGEN INC's drug REPATHA (SUPPL-49) with active ingredient EVOLOCUMAB has changed to 'Approval' on 07/15/2026. Application Category: BLA, Application Number: 125522, Application Classification:
- PRAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSVESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and e
- PRAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCETHOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found
- PRAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA® in IgG4-RD Real-World Evidence Supports TAVNEOS® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated VasculitisTHOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.New data from the Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD),1 while additional
AMGN FAQ
8 questionsWhat does Amgen Inc. do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic...Where does AMGN stock trade?
Amgen Inc. (AMGN) is listed on NASDAQ.What sector and industry is AMGN in?
Amgen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Amgen Inc. go public?
Amgen Inc. (AMGN) completed its IPO in 1983.Does AMGN pay a dividend?
AMGN's most recent ex-dividend date was 2026-08-21 with a cash dividend of $2.52 per share. No future ex-date is on file yet.What are analysts saying about AMGN?
Amgen Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Hold on 2026-08-05.What companies are similar to AMGN?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), PFE (Pfizer Inc.). Compare AMGN side-by-side with any of them on Quantisnow.How can I track AMGN on Quantisnow?
Quantisnow aggregates Amgen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMGN to receive live email and push alerts on every new disclosure.